Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” second quarter 2025 investor ...

Becton Dickinson (BDX) recently announced the initiation of a pharma-sponsored clinical trial featuring their BD Libertas Wearable Injector, alongside an affirmed quarterly dividend and leadership ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Becton, Dickinson and Company is an attractive firm that just made a good deal. Click here to find out why BDX stock is a Buy ...

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 ...

This was the stock's second consecutive day of losses.

Becton, Dickinson (NYSE:BDX) declares $1.04/share quarterly dividend, in line with previous. Forward yield 2.29% Payable Sept. 30; for shareholders of record Sept. 8; ex-div Sept. 8. See BDX Dividend ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” second quarter 2025 investor letter. The fund ...

Any one of the majors will be thrilled to snap some of these brands because there’s very little organic growth in the ...

Becton Dickinson (BDX) announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for ...

Waters Corporation announces a $17.5 billion acquisition of Becton Dickinson's bioscience unit, expanding its reach in ...